WO2013186493A2 - Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate - Google Patents

Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate Download PDF

Info

Publication number
WO2013186493A2
WO2013186493A2 PCT/FR2013/051380 FR2013051380W WO2013186493A2 WO 2013186493 A2 WO2013186493 A2 WO 2013186493A2 FR 2013051380 W FR2013051380 W FR 2013051380W WO 2013186493 A2 WO2013186493 A2 WO 2013186493A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
hyaluronic acid
sucrose octasulfate
soluble salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2013/051380
Other languages
English (en)
French (fr)
Other versions
WO2013186493A3 (fr
Inventor
Estelle Piron
Jérémie BON BETEMPS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Vivacy SAS
Original Assignee
Laboratoires Vivacy SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11201407857SA priority Critical patent/SG11201407857SA/en
Priority to CA2876057A priority patent/CA2876057A1/fr
Priority to PL13733396T priority patent/PL2861301T3/pl
Priority to PCT/FR2013/051380 priority patent/WO2013186493A2/fr
Priority to ES13733396T priority patent/ES2728686T3/es
Priority to EA201492208A priority patent/EA201492208A1/ru
Priority to KR20147036186A priority patent/KR20150023468A/ko
Priority to JP2015516668A priority patent/JP6178414B2/ja
Priority to MX2014013949A priority patent/MX354544B/es
Application filed by Laboratoires Vivacy SAS filed Critical Laboratoires Vivacy SAS
Priority to EP13733396.9A priority patent/EP2861301B1/fr
Priority to AU2013276343A priority patent/AU2013276343B2/en
Priority to BR112014029510A priority patent/BR112014029510A2/pt
Priority to CN201380031227.6A priority patent/CN104394934B/zh
Publication of WO2013186493A2 publication Critical patent/WO2013186493A2/fr
Publication of WO2013186493A3 publication Critical patent/WO2013186493A3/fr
Priority to IL235776A priority patent/IL235776A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • compositions comprising in combination with hyaluronic acid, a compound having the inhibitory properties of hyaluronidases.
  • compositions based on hyaluronic acid for example the patent application WO 03/041724 in the name of Hermida, describes injectable compositions. sterile based on a mixture of sodium hyaluronate and chondroitin sulfate for intraarticular targeting.
  • the present invention solves all the problems mentioned above and further allows to obtain compositions according to the invention retaining their rheological properties during autoclaving and having a higher remanence (half-life time). higher) compared to the compositions of the prior art.
  • the composition according to the invention is characterized in that the mass ratio between the content of hyaluronic acid [HA] and the water-soluble salt content of sucrose octasulfate [SOS], [HA] / [ SOS] is between 1 and 1000.
  • the composition according to the invention is characterized in that the water-soluble salt content of sucrose octasulfate is between 0.1 mg / g and 1 mg / g of composition. In one embodiment, the composition according to the invention is characterized in that the hyaluronic acid content is between 2 mg / g and 50 mg / g of composition.
  • the composition according to the invention is characterized in that it comprises a mixture of crosslinked hyaluronic acids.
  • said compositions are used as artificial tears, lacrimal gels or lubricants.
  • the NaHA hydrogel obtained in the preceding step is diluted by addition of the aqueous potassium sucrose octasulfate solution previously prepared. The composition thus obtained is then homogenized.
  • Example 2 [000145] This example illustrates an exemplary composition according to the invention comprising crosslinked hyaluronic acid and potassium sucrose octasulfate.
  • This example illustrates an example of a composition according to the invention comprising crosslinked hyaluronic acid, potassium sucrose octasulfate and lidocaine.
  • a composition comprising crosslinked NaHA is prepared according to the procedure described in Example 2 from a NaHA hydrogel at a concentration of 30 mg / g and potassium sucrose octasulfate at a concentration of 10 mg / ml. boy Wut.
  • the addition of a solution of lidocaine at a concentration of 13 mg / g to the composition obtained above is carried out according to the procedure described in WO 2009/024670 in the name of ANTEIS or according to the procedure described in US Pat. US 61 / 791,977 or FR 13/52971 in the name of VI ACY.
  • the NaHA hydrogel obtained in the preceding step is diluted by addition of the aqueous potassium sucrose octasulfate solution previously prepared. The composition thus obtained is then homogenized.
  • compositions comprising crosslinked hyaluronic acid, mannitol and a sulfated oligo-polysaccharide or a sulfated ose at a concentration of 1 mg / g in the composition is prepared according to the procedure described in the example 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/FR2013/051380 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate Ceased WO2013186493A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2014013949A MX354544B (es) 2012-06-13 2013-06-13 Composicion, en medio acuoso, que comprende al menos un acido hialuronico y al menos una sal hidrosoluble de octasulfato de sacarosa.
PL13733396T PL2861301T3 (pl) 2012-06-13 2013-06-13 Kompozycja zawierająca, w środowisku wodnym, co najmniej jeden kwas hialuronowy i co najmniej jedną rozpuszczalną w wodzie sól oktasiarczanu sacharozy
EP13733396.9A EP2861301B1 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
ES13733396T ES2728686T3 (es) 2012-06-13 2013-06-13 Composición, en un medio acuoso, que comprende al menos un ácido hialurónico y al menos una sal hidrosoluble de octasulfato de sacarosa
EA201492208A EA201492208A1 (ru) 2012-06-13 2013-06-13 Композиция в водной среде, включающая по меньшей мере одну гиалуроновую кислоту и по меньшей мере одну водорастворимую соль октасульфата сахарозы
KR20147036186A KR20150023468A (ko) 2012-06-13 2013-06-13 하나 이상의 히알루론산 및 하나 이상의 수크로스 옥타설페이트 수용성 염을 포함하는 수성 매질 중 조성물
JP2015516668A JP6178414B2 (ja) 2012-06-13 2013-06-13 少なくとも１種のヒアルロン酸及び少なくとも１種のショ糖オクタ硫酸水溶性塩を含有する水性媒体組成物
SG11201407857SA SG11201407857SA (en) 2012-06-13 2013-06-13 Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt
PCT/FR2013/051380 WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
CA2876057A CA2876057A1 (fr) 2012-06-13 2013-06-13 Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
AU2013276343A AU2013276343B2 (en) 2012-06-13 2013-06-13 Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt
BR112014029510A BR112014029510A2 (pt) 2012-06-13 2013-06-13 composição esterilizada e meio aquoso compreendendo, pelo menos, um ácido hialurônico e, pelo menos, um sal hidrossolúvel de sacarose octassulfato, processo de fabricação, e de utilização da mesma, formulação cosméstica, e, kit
CN201380031227.6A CN104394934B (zh) 2012-06-13 2013-06-13 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物
IL235776A IL235776A0 (en) 2012-06-13 2014-11-18 A preparation in an aqueous medium containing at least hyaluronic acid and at least a water-soluble salt of sucrose octasulfate

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659140P 2012-06-13 2012-06-13
US61/659,140 2012-06-13
FR1255543 2012-06-13
FR1255543A FR2991876B1 (fr) 2012-06-13 2012-06-13 Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
PCT/FR2013/051380 WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate

Publications (2)

Publication Number Publication Date
WO2013186493A2 true WO2013186493A2 (fr) 2013-12-19
WO2013186493A3 WO2013186493A3 (fr) 2014-05-08

Family

ID=46785648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2013/051380 Ceased WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate

Country Status (17)

Country Link
US (1) US9314530B2 (enExample)
EP (1) EP2861301B1 (enExample)
JP (1) JP6178414B2 (enExample)
KR (1) KR20150023468A (enExample)
CN (1) CN104394934B (enExample)
AU (1) AU2013276343B2 (enExample)
BR (1) BR112014029510A2 (enExample)
CA (1) CA2876057A1 (enExample)
EA (1) EA201492208A1 (enExample)
ES (1) ES2728686T3 (enExample)
FR (1) FR2991876B1 (enExample)
IL (1) IL235776A0 (enExample)
MX (1) MX354544B (enExample)
PL (1) PL2861301T3 (enExample)
SG (1) SG11201407857SA (enExample)
TR (1) TR201907427T4 (enExample)
WO (1) WO2013186493A2 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015407A1 (en) 2013-07-30 2015-02-05 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290A1 (fr) * 2013-12-23 2015-06-26 Vivacy Lab Compositions d'acide hyaluronique compreant de la mepivacaine
FR3032617A1 (fr) * 2015-02-16 2016-08-19 Benedicte Vincente Gavard Molliard Tauzin Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
WO2016180904A1 (fr) 2015-05-11 2016-11-17 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
WO2017053339A1 (en) * 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
WO2017102001A1 (fr) 2015-12-16 2017-06-22 Vplus International Sa Composition d'acide hyaluronique pour injections peniennes
FR3047666A1 (fr) * 2016-02-15 2017-08-18 Benedicte Vincente Gavard Molliard Tauzin Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
EP3315130A1 (fr) 2016-10-28 2018-05-02 Laboratoires Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaïne
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
US10383890B2 (en) 2013-07-10 2019-08-20 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2021205037A1 (en) 2020-04-10 2021-10-14 Teoxane SA Compositions based on at least two glycosaminoglycans

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2898656T3 (es) * 2014-06-30 2022-03-08 Nutricos Tech Productos de combinación y composiciones cosméticas para luchar contra los trastornos de la piel y su envejecimiento que afectan a los queratinocitos y/o los fibroblastos y la dermis
CN104926889A (zh) * 2015-05-24 2015-09-23 广西师范学院 蔗糖硫酸酯铜银类化合物及其制作方法和用途
FR3044557B1 (fr) * 2015-12-07 2017-12-01 Benedicte Vincente Gavard Molliard Tauzin Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
WO2018107226A1 (en) * 2016-12-13 2018-06-21 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
BR112019012045A2 (pt) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd inibidores de heparanase e uso dos mesmos
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
KR102664134B1 (ko) * 2023-11-23 2024-05-10 한국콜마주식회사 히알루론산 및 이의 유도체를 포함하는 화장료 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2715091A (en) 1949-11-28 1955-08-09 Nat Res Dev Dextran sulfate as anticoagulant, process of preparing same, and sterile solution thereof
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5916880A (en) 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
DK86492D0 (da) 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
WO1998022114A1 (en) 1996-11-15 1998-05-28 Dumex-Alpharma A/S A method for promoting tissue repair
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
GB9902412D0 (en) 1999-02-03 1999-03-24 Fermentech Med Ltd Process
EP1423081A4 (en) * 2001-06-25 2005-05-25 Depuy Int Ltd COMPOSITION WITH GLYCOSAMINOGYCANES AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC JOINTS
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
AUPS052802A0 (en) 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US20080003258A1 (en) 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
AU2003295347B2 (en) 2002-10-16 2010-02-11 Arthrodynamic Holdings, Llc Treatment for traumatic synovitis and damaged articular cartilage
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
GB0329907D0 (en) 2003-12-23 2004-01-28 Innomed Ltd Compositions
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20090215717A1 (en) 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
MX2009000885A (es) 2006-07-25 2009-02-05 Osmotica Corp Soluciones oftalmicas.
JPWO2008020495A1 (ja) * 2006-08-15 2010-01-07 東京化成工業株式会社 新規阻害剤
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
ITMI20072237A1 (it) 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2953522B1 (fr) 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
FR2956322A1 (fr) 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
CA2805008C (en) * 2010-07-12 2015-05-12 Shin Poong Pharmaceutical Co., Ltd. Filler composition for tissue augmentation comprising a hydrogel of hyaluronic acid cross-linked with alkylene diamine
FR2983483B1 (fr) 2011-12-02 2014-11-14 Vivacy Lab Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524027B2 (en) 2013-07-10 2022-12-13 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US10933085B2 (en) 2013-07-10 2021-03-02 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US10383890B2 (en) 2013-07-10 2019-08-20 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2015015407A1 (en) 2013-07-30 2015-02-05 Teoxane Composition comprising hyaluronic acid and mepivacaine
US11406738B2 (en) 2013-07-30 2022-08-09 Teoxane Composition comprising hyaluronic acid and mepivacaine
EP3574901B1 (en) 2013-07-30 2022-01-26 Teoxane Injection devices comprising a composition of hyaluronic acid and mepivacaine hydrochloride
EP3574901A1 (en) * 2013-07-30 2019-12-04 Teoxane Injection devices comprising a composition of hyaluronic acid and mepivacaine hydrochloride
EP3027186B1 (en) * 2013-07-30 2019-06-19 Teoxane Process for the preparation of compositions comprising hyaluronic acid and mepivacaine hydrochloride
EP3173086A1 (fr) 2013-12-23 2017-05-31 Laboratoires Vivacy Compositions d'acide hyaluronique comprenant de la mépivacaïne
EA036502B1 (ru) * 2013-12-23 2020-11-17 Лаборатуар Виваси Композиции гиалуроновой кислоты, включающие мепивакаин
FR3015290A1 (fr) * 2013-12-23 2015-06-26 Vivacy Lab Compositions d'acide hyaluronique compreant de la mepivacaine
WO2015097261A1 (fr) * 2013-12-23 2015-07-02 Laboratoires Vivacy Compositions d'acide hyaluronique comprenant de la mepivacaïne
KR20160096205A (ko) * 2013-12-23 2016-08-12 라보라뚜와 비바시 메피바카인을 포함하는 히알루론산 조성물
KR102343660B1 (ko) 2013-12-23 2021-12-28 라보라뚜와 비바시 메피바카인을 포함하는 히알루론산 조성물
EP3799875A1 (fr) * 2013-12-23 2021-04-07 Laboratoires Vivacy Compositions d'acide hyaluronique comprenant de la mépivacaïne
EA031349B1 (ru) * 2013-12-23 2018-12-28 Лаборатуар Виваси Композиция гиалуроновой кислоты, включающая мепивакаин
FR3044228A1 (fr) * 2013-12-23 2017-06-02 Lab Vivacy Compositions d'acide hyaluronique comprenant de la mepivacaine
JP2017500358A (ja) * 2013-12-23 2017-01-05 ラボラトアール ヴィヴァシィ メピバカインを含有するヒアルロン酸組成物
AU2014372513B2 (en) * 2013-12-23 2020-04-30 Laboratoires Vivacy Hyaluronic acid compositions including mepivacaine
FR3032617A1 (fr) * 2015-02-16 2016-08-19 Benedicte Vincente Gavard Molliard Tauzin Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
WO2016180904A1 (fr) 2015-05-11 2016-11-17 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
EP3842047A1 (en) * 2015-09-24 2021-06-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
US10888580B2 (en) 2015-09-24 2021-01-12 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
WO2017053339A1 (en) * 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
US10383889B2 (en) 2015-09-24 2019-08-20 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
US11583549B2 (en) 2015-09-24 2023-02-21 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
WO2017102001A1 (fr) 2015-12-16 2017-06-22 Vplus International Sa Composition d'acide hyaluronique pour injections peniennes
WO2017140958A1 (fr) * 2016-02-15 2017-08-24 Tauzin Bénédicte Vincente Composition injectable; procédé de préparation de ladite composition; utilisation de ladite composition
FR3047666A1 (fr) * 2016-02-15 2017-08-18 Benedicte Vincente Gavard Molliard Tauzin Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
EP3315130A1 (fr) 2016-10-28 2018-05-02 Laboratoires Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaïne
WO2021205037A1 (en) 2020-04-10 2021-10-14 Teoxane SA Compositions based on at least two glycosaminoglycans
FR3109153A1 (fr) 2020-04-10 2021-10-15 Teoxane SA Compositions à base d’au moins deux glycosaminoglycanes

Also Published As

Publication number Publication date
CN104394934A (zh) 2015-03-04
JP2015525099A (ja) 2015-09-03
AU2013276343B2 (en) 2017-06-15
AU2013276343A1 (en) 2014-12-04
IL235776A0 (en) 2015-01-29
KR20150023468A (ko) 2015-03-05
EP2861301B1 (fr) 2019-02-20
CN104394934B (zh) 2018-01-09
PL2861301T3 (pl) 2020-08-24
FR2991876B1 (fr) 2014-11-21
TR201907427T4 (tr) 2019-06-21
EA201492208A1 (ru) 2015-04-30
MX2014013949A (es) 2015-05-11
BR112014029510A2 (pt) 2017-06-27
MX354544B (es) 2018-03-09
SG11201407857SA (en) 2015-02-27
WO2013186493A3 (fr) 2014-05-08
US9314530B2 (en) 2016-04-19
JP6178414B2 (ja) 2017-08-09
ES2728686T3 (es) 2019-10-28
CA2876057A1 (fr) 2013-12-19
EP2861301A2 (fr) 2015-04-22
FR2991876A1 (fr) 2013-12-20
US20140005140A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
EP2861301B1 (fr) Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
EP2890360B1 (fr) Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
EP2173324B1 (fr) Gel injectable d'acide hyaluronique pour le traitement des degenerescences articulaires
CA2932967C (fr) Compositions d'acide hyaluronique comprenant de la mepivacaine
FR2920000A1 (fr) Composition cosmetique ou pharmaceutique contenant de l'acide hyaluronique, et procede cosmetique pour diminuer les signes du vieilissement
WO2012104419A1 (en) Hyaluronic acid composition
EP2155149A2 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
ES2660847T3 (es) Ésteres fórmicos butíricos mezclados de polisacáridos ácidos, y su preparación y uso como cosméticos para la piel
FR2977494A1 (fr) Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes
EP3510050A1 (fr) Chitosane à charge anionique
EP4508133A1 (fr) Hydrogels pour le comblement des tissus mous
CA3127577A1 (fr) Composition cosmetique/dermatologique
FR3074044B1 (fr) Carboxyalkyl chitosane
FR3134577A1 (fr) Procede de preparation d’un hydrogel comprenant un polysaccharide silyle reticule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13733396

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/013949

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 235776

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2015516668

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013276343

Country of ref document: AU

Date of ref document: 20130613

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2876057

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2013733396

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147036186

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201492208

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014029510

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014029510

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141126